- Report
- May 2024
- 88 Pages
Global
From €5320EUR$5,600USD£4,577GBP
- Report
- February 2024
- 200 Pages
Global
From €4750EUR$5,000USD£4,086GBP
- Report
- November 2023
- 149 Pages
Global
From €2374EUR$2,499USD£2,042GBP
- Report
- July 2023
- 145 Pages
Global
From €2993EUR$3,150USD£2,574GBP
- Report
- October 2023
- 146 Pages
Global
From €3351EUR$3,528USD£2,883GBP
€3943EUR$4,150USD£3,392GBP
- Report
- November 2023
- 162 Pages
Global
From €5653EUR$5,950USD£4,863GBP
- Report
- November 2023
- 250 Pages
Global
From €4750EUR$5,000USD£4,086GBP
- Report
- June 2023
- 113 Pages
Global
From €4275EUR$4,500USD£3,678GBP
- Report
- March 2024
- 200 Pages
Global
From €3943EUR$4,150USD£3,392GBP
- Report
- July 2023
- 220 Pages
Global
€4555EUR$4,795USD£3,919GBP
- Report
- July 2023
- 89 Pages
Middle East
From €4180EUR$4,400USD£3,596GBP
- Report
- February 2024
- 75 Pages
Asia Pacific
From €4513EUR$4,750USD£3,882GBP
- Report
- July 2022
- 84 Pages
Global
From €5225EUR$5,500USD£4,495GBP
- Report
- February 2024
- 128 Pages
From €3373EUR$3,550USD£2,901GBP
- Report
- June 2022
- 115 Pages
Global
From €4513EUR$4,750USD£3,882GBP
- Report
- November 2019
- 141 Pages
From €1995EUR$2,100USD£1,716GBP
€2850EUR$3,000USD£2,452GBP
- Report
- January 2023
- 154 Pages
Global
From €4228EUR$4,450USD£3,637GBP
- Report
- December 2019
- 101 Pages
Global
From €4228EUR$4,450USD£3,637GBP
- Report
- January 2022
- 112 Pages
Middle East, Africa
From €1425EUR$1,500USD£1,226GBP
- Report
- January 2024
- 120 Pages
Global
From €3500EUR$3,946USD£3,116GBP
The Recombinant DNA market is a subset of the genomics industry, which focuses on the manipulation of genetic material to create new products. It involves the use of recombinant DNA technology to modify existing DNA sequences, or to create new ones. This technology is used to produce a variety of products, such as therapeutic proteins, vaccines, and diagnostics. It is also used in research and development, as well as in the production of genetically modified organisms.
The Recombinant DNA market is driven by the increasing demand for biopharmaceuticals, as well as the need for more efficient and cost-effective production of these products. Additionally, the development of new technologies, such as gene editing, is expected to further drive the market.
Some of the major companies in the Recombinant DNA market include Amgen, Novartis, Merck, Pfizer, and Johnson & Johnson. Other notable players include AbbVie, AstraZeneca, Bristol-Myers Squibb, and GlaxoSmithKline. Show Less Read more
